Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

← catalyst calendar

NCT05725018

Sponsored by Abeona Therapeutics, Inc (industry) · ABEO — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
2
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-04-02actualWhen the study began enrolling
Primary completion2025-09-30estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-09-30estimatedThe whole study's end, after follow-up
First posted2023-02-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-06-27actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • RDEB

Intervention

  • Biological: EB-101 Surgical application of RDEB wounds — also filed as pz-cel

Primary outcomes

what the primary-completion date above is the date OF
Safety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
measured 6 months
Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.)
measured 6 months
Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )
measured 6 months
Safety Endpoint (Incidence of squamous cell carcinoma)
measured 6 months
Safety Endpoint RCR status
measured 6 months

Permalink · ABEO's whole pipeline · Catalyst calendar · Every registered study · What changed